PROWESS Investigators[Corporate Author] - Search Results

Your saved search

Your RSS Feed

Year	Number of Results
2003	2
2004	1
2025	0

Page 1

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators. Ely EW, et al. Crit Care Med. 2003 Jan;31(1):12-9. doi: 10.1097/00003246-200301000-00002. Crit Care Med. 2003. PMID: 12544987 Clinical Trial.

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators. Angus DC, et al. Crit Care Med. 2004 Nov;32(11):2199-206. doi: 10.1097/01.ccm.0000145228.62451.f6. Crit Care Med. 2004. PMID: 15640631 Free PMC article.

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.

Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B; PROWESS Investigators. Angus DC, et al. Crit Care Med. 2003 Jan;31(1):1-11. doi: 10.1097/00003246-200301000-00001. Crit Care Med. 2003. PMID: 12544986 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year